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esomeprazole. METHODS: The number of patients with GERD
was derived from epidemiological studies. The number of proton
pump inhibitor (PPI) users was calculated from IMS publications
and reimbursement data provided by sick-funds. According to
clinical practice, in future, the number of patients taking a PPI
will be the number of weekly GERD sufferers. Alternatively,
future PPI users will comprise patients currently receiving a PPI
plus those currently using H2-receptor antagonists, plus a large
part of current antacids users. Results of on-demand treatment
come from the ONE study (2-arm parallel study over a 6-month
maintenance period, on-demand versus continuous therapy with
esomeprazole 20mg). RESULTS: A totla of 28% of the Belgian
adult population (n = 10 million) have GERD symptom(s), 11%
weekly, 4% daily. Assuming stable prevalence of GERD over the
next decade, the number of PPI-treated patients could reach
approximately 920,000/year from 446,000 currently. Yearly
expenses would therefore increase from 149€ to 248€ million.
This would be reached by 2010 with linear growth or 2005 with
exponential growth. In 2652 Belgian patients with a similar
proﬁle to the screened population of the epidemiological studies,
the ONE study showed on-demand treatment (mean daily
intake: 0.6 tablet) was similar to continuous treatment (1
tablet/day) for patient satisfaction (92% in both groups), heart-
burn relapse (11.3% vs. 9.4%, respectively) and GERD-related
co-medication intake (8% vs. 7.3%, respectively). Over a 7-
month treatment period (4 weeks of acute treatment then 6
months’ maintenance), on-demand esomeprazole 20mg would
save approximately 27.5% on medication costs compared with
continuous esomeprazole therapy. CONCLUSIONS: Increasing
costs due to the expected increased use of PPI’s can be lowered
by using an effective PPI with an on-demand approach, which
maintains high patient satisfaction and efﬁcacy.
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OBJECTIVES: Gastro Esophageal Reﬂux Disease (GERD) is a
chronic condition that may affect patients’ quality of life. It is
one of the most common complaints in primary care settings
with relevant consequences on health economics in terms of
increasing health costs and limiting resources. An objective 
of this multicentre trial was to evaluate the time of action of
rabeprazole 20mg daily (RAB) and omeprazole 20mg daily
(OME) in inducing symptom relief in patients with reﬂux
oesophagitis in the curative phase. A prospective health eco-
nomic analysis was performed to compare the costs of the 2
treatments in obtaining symptoms improvement. METHODS: A
total of 484 patients, with mild to severe reﬂux oesophagitis
(Savary-Miller grade I to III), were randomised in a double-blind,
parallel group fashion, to receive RAB or OME for a period of
4 to 8 weeks with control visits every two weeks. The patients
had to ﬁll in a daily diary regarding to the number of tablets/cap-
sules taken, and the daytime and night time heartburn intensity
using the following score: absent, mild, moderate, severe and ter-
rible. The economic analysis was designed and carried out from
a societal and National Health Service perspective. RESULTS: In
the curative phase of reﬂux oesophagitis (4–8 weeks) treatment
with RAB (20mg) resulted less expensive than OME (20mg).
The estimated mean total costs were found to be lower in RAB
group (58.04€) than in the OME one (64.34€; p < 0.001). With
regard to numbers of symptom-free days, RAB (67.1%) was
found to be more effective than OME (66.8%). CONCLU-
SIONS: Rabeprazole (20mg) once daily is cost effective com-
pared with omeprazole (20mg) once daily in the curative phase
of reﬂux oesophagitis. Rabeprazole represents good value for
money and efﬁcient use of health care resources in the treatment
of reﬂux oesophagitis.
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OBJECTIVES: Endoscopic and laparoscopic surgeries are now
widely used to treat patients with stones in gallbladder and
common bile duct (CBD). The objectives of this study were to
compare the economic and clinical results between two methods
in the treatment of stones in gallbladder and CBD. METHODS:
A computer model was established to assess the cost-beneﬁt of
two types of treatment from the provider’s perspective. Treat-
ment A provided two-stage procedure, which performs endo-
scopic sphincterotomy (EST) ﬁrst and then followed by
laparoscopic cholecystectomy (LC) (EST + LC). Treatment B is
a one-stage procedure that performs laparoscopic surgery alone
to remove both the gallbladder and stones in common bile duct
(LCBDE + LC). Sources of parameters for the simulation model
came from the results of published articles and patients received
endoscopic and/or laparoscopic surgery in a medical center.
RESULTS: Treatment B had a better successful rate than that of
treatment A and a shorter length of hospital stay. However, treat-
ment A had better stone removal rate. Under current insurance
payment schedule, the net beneﬁt of treatment A is NT$ 16,816
and NT$ -11,603 for treatment B. Therefore, it will be cost-ben-
eﬁcial to do EST + LC under current payment schedule. Sensi-
tivity analysis showed that hospitals must reduce the cost of
LCBDE + LC to NT$ 44,500 to avoid loss (currently NT$
85,513). If the cost of LCBDE + LC can be reduced to 33,000,
it can achieve the same beneﬁt as EST + LC. CONCLUSIONS:
Providers should hold the therapy of EST + LC to be the major
treatment under current insurance payment schedule. LCBDE +
LC is not commonly performed in Taiwan because of insufﬁcient
payment. However, it has the advantage of reducing patients’
suffering, shorter operation waiting time, and shorter hospital
stay. It would be beneﬁcial to patients if hospitals can reduce the
cost of LCBDE + LC and perform the procedure when appro-
priate.
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OBJECTIVES: There have been only a few studies published in
the world literature to date dealing with the pharmacoeconom-
ics of Crohnxs disease including east and central European coun-
tries. METHODS: The retrospective cost of illness study was
carried out by the analysis of all medical records and by special
questionnaire of patients suffering from Crohnxs disease in
1999–2000. RESULTS: Of 54 patients, 30 women, and 24 men,
with the average age of 48.8 years and with the average dura-
tion of illness of 75.8 months, were divided into 3 subgroups
from the point of view of pharmacoeconomics: A,—uncompli-
cated, 24 persons, B,—with chronic corticosteroid treatment, 12
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persons, and C,—with surgery to cure the disease itself or its
complications, 18 persons. The average costs were 1060€ per
person and year. The average of yearly costs per person in the
subgroup A were 485€; in the subgroup B it was 1500€, and in
the subgroup C, it was 1,530€. The highest costs per one patient
in the subgroup B were 4265€ and in subgroup C it was 6255€.
The ratio of own patients to all costs was 17.5%, to health care
costs 72.1%, and to social costs 10.4%. Pharmacotherapy
reached 49.7% of the total costs, diagnostic procedures 0.9%,
ambulatory care 19.0%, hospital care 26%, spa care and travel
costs 4.4%. CONCLUSIONS: Crohnxs disease belongs to the
more expensive diseases in the Slovak Republic. There is a sig-
niﬁcant difference in the ratio-structure of costs in comparison
with western countries and the USA. Next pharmacoeconomic
studies in the Slovak Republic should be designed as prospec-
tive, cost of utility studies.
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OBJECTIVES: Overlap of gastro-oesophageal reﬂux disease
(GERD) and peptic ulcer disease (PUD) in a population with high
prevalence of Helicobacter pylori infections creates clinical
dilemmas in Hong Kong. Testing and eradication of H. pylori
may be a cost-effective alternative for empirical proton-pump
inhibitor (PPI) therapy. To examine the potential clinical and eco-
nomic impact of H. pylori “test and treat” and empirical PPI
therapy for GERD patients with typical reﬂux and high preva-
lence of H. pylori infection. METHODS: A Markov model was
designed to simulate the outcomes of the two treatment strate-
gies over 12 months. The transition probabilities and resource
utilization were derived from literature. Percentage of patients
with PUD treated, total number of quality-adjusted life-years
(QALY’s) gained and total direct medical cost were estimated.
RESULTS: H. pylori “test & treat” was more effective (92.6%
ulcer treated and 0.919 QALYs gained) than empirical PPI
(72.6% ulcer treated and 0.909 QALYs gained). The direct
medical cost per patient in the H. pylori “test and treat” and
empirical PPI arms were USD1901 and USD1770, respectively.
The direct medical cost per patient was sensitive to the variation
of the prevalence of PUD in H. pylori-infected GERD patients.
CONCLUSIONS: H. pylori “test & treat” appeared to be more
effective than empirical PPI therapy, with an incremental cost,
for GERD patients with typical reﬂux in Hong Kong.
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OBJECTIVES: To assess health related quality of life (QOL) and
its predictors among Polish patients with gastroesophageal reﬂux
disease (GERD). METHODS: National survey study was carried
out among 192 Polish general practitioners on out-patients pre-
senting with GERD symptoms. Data on patients’ clinical char-
acteristics, symptoms, treatment and QOL were collected. The
Carlsson’s diagnostic test was used to assess symptoms. A cut-
off score of four or higher was considered positive for GERD.
QOL was measured with SF-36. For the statistical hypothesis
testing the signiﬁcance threshold was set to 0.01. RESULTS:
Data on QOL was collected for 3290 patients, mean age: 
48.9 years (95%CI: 48.4–49.4; males: 47.8% (95%CI:
46.1%–49.5%). Mean health related QOL score was 58.5
(95%CI: 57.9–59.2). Patients with longer history of GERD-asso-
ciated symptoms reported statistically signiﬁcantly lower QOL
(19.1% decrease in QOL for patients with gastroesophageal
reﬂux disease history lasting for ﬁve to 10 years compared to
patients reporting it for less than three months). Adjusting for
case-mix the following symptoms were associated with statisti-
cally signiﬁcantly lower QOL: dysphagia, odynophagia, weight
loss, anaemia, age over 65, hoarseness, rhonchus, fullness, vom-
iting, while heartburn and chest pain or burning sensation and
chronic cough were not. CONCLUSIONS: GERD is associated
with poor QOL, especially for chronic patients. Some symptoms
represent good predicting value for QOL deterioration.
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OBJECTIVES: Gastrointestinal (GI) complications associated
with immunosuppressants are frequently reported by renal trans-
plant recipients. Mycophenolic acid has been associated with an
increased incidence of GI complaints. GI complications may
affect patient Quality of Life (QoL). The purpose of this study
was to psychometrically validate two GI-speciﬁc patient-
reported outcome (PRO) instruments in the renal transplant pop-
ulation. METHODS: The Gastrointestinal Symptom Rating
Scale (GSRS) and Gastrointestinal Quality of Life Index (GIQLI)
were selected for validation. Renal transplant recipients receiv-
ing a calcineurin inhibitor and mycophenolate mofetil were
recruited in a cross-sectional study from 5 clinical centers across
4 countries. Patients completed the GSRS, GIQLI, Psychological
General Well-Being Index (PGWB) and EQ-5D. Statistical analy-
ses employed Cronbach’s alpha, correlations, t-tests and
ANOVA. RESULTS: Of 96 patients recruited (mean age: 47.4 +
12.3 years; male: 56%), 41 (43%) suffered from no, 37 (39%)
mild, 12 (13%) moderate, and 6 (6%) severe GI symptoms.
Internal consistency reliability (Cronbach’s alpha) was >0.7 for
all GIQLI and all but 1 of the GSRS dimensions (abdominal
pain). Correlations between GIQLI and PGWB and EQ-5D were
higher (range: 0.24–0.76) than correlations between GSRS and
PGWB and EQ-5D (range: 0.05–0.54). All GSRS subscales and
the GIQLI total score and 4 subscales signiﬁcantly differentiated
between patients with and without GI complications (p < 0.05),
as did the PGWB total score and EQ-5D. The generic instru-
ments were unable to discriminate between GI severity levels;
conversely, the disease-speciﬁc instruments discriminated to
some extent between GI severity levels. GSRS abdominal pain
subscale discriminated between patients at all levels of severity
